CBP-201, an anti-IL-4Ra antibody, is in clinical trial development to treat atopic dermatitis (AD) patients with moderate-to-severe AD. A Phase 2b study in this population showed CBP-201 met the primary endpoint of eczema area and severity index (EASI) percent reduction from baseline at Week 16 and were statistically superior to placebo. Clinical trials are ongoing for CBP-201 in patients with moderate-to-severe atopic dermatitis (AD) and moderate-to-severe persistent asthma with type 2 inflammation.
CBP-307, a small molecule modulator of S1P1, is currently being evaluated in a global Phase 2 clinical study in patients with ulcerative colitis. CBP-307 is not a pro-drug and does not require conversion to an active form in the human body following administration.
We are developing CBP-174, a peripherally acting, small molecule H3R antagonist, for oral administration to treat chronic pruritus associated with skin inflammation. CBP-174 is currently being evaluated in a Phase 1 dose-escalation study in healthy subjects. Our preclinical models have indicated that CBP-174 led to reductions in scratching in mice within the first 30 minutes of dosing, which could potentially translate to rapid reduction in pruritus in the clinic.
- Connect Biopharma and Simcere Announce Exclusive Licensing and Collaboration Agreement in Greater China
- Connect Biopharma Announces Positive Long-Term Data from the China Pivotal Trial of Rademikibart in Patients with Moderate-to-Severe Atopic Dermatitis
- Connect Biopharma to Announce Long-Term Data from the China Pivotal Trial of Rademikibart in Patients with Moderate-to-Severe Atopic Dermatitis on November 21, 2023